CGClaire Guissart

Claire Guissart

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Claire Guissart has a total of 138 co-authors. Here are the top co-authors by number of shared publications:

  • Michel Koenig

    Laboratoire de Génétique de Maladies Rares EA7402, Institut Universitaire de Recherche Clinique, Université de Montpellier, CHU Montpellier, 640 av. Doyen G. Giraud CEDEX 5, 34295, Montpellier, France

    5 shared publications
  • Anne Polge

    Laboratoire de Biochimie et Biologie Moléculaire, CHU Nîmes, Nîmes, France

    4 shared publications
  • Cédric Raoul

    INM, Univ Montpellier, INSERM, Montpellier, France

    4 shared publications
  • Mireille Claustres

    Laboratoire de Génétique de Maladies Rares EA7402, Institut Universitaire de Recherche Clinique, Université de Montpellier, CHU Montpellier, 640 av. Doyen G. Giraud CEDEX 5, 34295, Montpellier, France

    4 shared publications
  • Emilien Bernard

    Hospices Civils de Lyon, Neurological Hospital Pierre-Wertheimer, Lyon, France

    3 shared publications
  • Kevin Mouzat

    Laboratoire de Biochimie et Biologie Moléculaire, CHU Nimes, Univ Montpellier, Nîmes, France

    3 shared publications

Latest Publications

  • Open Access

    Pathogenic NLGN4X variants reveal dual roles in synaptic connectivity and cortical development

    by Eunhye Hong, Miriam Reyes Mendez, Claire Guissart, Khaoula Zaafrane-Khachnaoui, Abhijeet Kapoor, Patrycja Brzdąk, John D. Badger, Wei Lu, Katherine W. Roche

    Neuroligins are synaptic adhesion molecules important for neurodevelopment, and rare, highly penetrant variants underlie neurodevelopmental disorders (NDDs). Here, we characterize a rare missense variant NLGN4X G243R identified in a pedigree with NDDs and associated with severe protein trafficking deficits. NLGN4X G243R lies within a cluster of rare NLGN4X variants (amino acids 235-245), all of which impair trafficking. Using biochemical, imaging, and electrophysiological approaches, we find that these NLGN4X variants exhibit severe trafficking defects, leading to impaired cell surface localization and synaptogenesis. Structural modeling further suggests that the NLGN4X NDD-variants destabilize protein conformation which is supported by thermal stability assessment. Notably, we uncover a previously unrecognized role for NLGN4X in regulating neuronal migration during early brain development, extending its functional scope beyond synaptogenesis. Collectively, these results show that NDD-associated NLGN4X variants disrupt both synapse formation and neuronal migration, offering mechanistic insight into their contribution to neurodevelopmental pathology and highlighting potential therapeutic avenues.

  • Identification de nouveaux gènes d'ataxies récessives syndromiques : implication des désordres métaboliques modérés

    by Claire Guissart

    Les ataxies héréditaires représentent un groupe hétérogène de maladies neurodégénératives caractérisées par des anomalies de la coordination des mouvements associées à des troubles de l’équilibre et de la marche. L’immense diversité fonctionnelle des protéines touchées dans les ataxies autosomiques récessives (AR) souligne que celles-ci ne peuvent pas être classées selon les voies physiopathologiques en cause. De ce constat résulte une classification émergente des AR en fonction de la raison expliquant la nature « modérée » de l’atteinte neurologique, à savoir : (i) les mutations avec perte de fonction partielle, (ii) la présence redondante de protéines de la même famille fonctionnelle, (iii) la présence redondante d’autres voies détoxifiantes. L’objectif de ce travail était d’identifier de nouveaux gènes responsables d’AR syndromiques grâce à une stratégie couplant la cartographie par homozygotie et l’analyse d’exomes de larges familles consanguines. L’analyse par génotypage de l’une de ces familles nous a permis d’identifier 2 régions homozygotes partagées par les 3 enfants atteints par le syndrome de Lichtenstein-Knorr (ataxie-surdité). Parmi les variants présents dans ces régions, j’ai identifié une mutation faux-sens dans le gène SLC9A1 codant pour l'échangeur Na+/H+1, NHE1. Cette mutation transforme la Glycine 305, un petit acide aminé très conservé et localisé dans le 8ème domaine transmembranaire, en Arginine, acide aminé chargé positivement. Bien que NHE1 soit une protéine exprimée de façon ubiquitaire, 2 modèles souris « knock-out » de ce gène ont montré sa fonction essentielle au niveau des noyaux profonds cérébelleux, vestibulaires et cochléaires où a été observé une dégénérescence spécifique suite à l’inactivation du gène Slc9a1. Nous avons ensuite apporté la preuve de l’effet délétère de la mutation p.Gly305Arg en montrant une réduction importante mais pas totale de l’activité de l’échangeur muté ainsi qu’une abolition de son expression à la surface cellulaire, démontrant ainsi que SLC9A1 est le gène impliqué dans le syndrome de Lichtenstein-Knorr (Guissart et al. Hum Mol Genet 2015). L’analyse de l’exome d’une famille consanguine multi-générationnelle présentant une ataxie spino-cérébelleuse, une cécité et une surdité et dont le locus avait été identifié par notre équipe en 2000 sur le chromosome 6p23-p21 (SCAR3 ; MIM #271250) m’a permis d’identifier la mutation faux-sens homozygote p.Gly306Arg dans le gène SLC52A2, pourtant située sur le chromosome 8qter et déjà décrite chez des patients atteints du syndrome de Brown-Vialetto-Van Laere type 2, indiquant que la liaison génétique initialement publiée pour cette famille était due au hazard. Le séquençage d’exome d'une autre famille avec 2 enfants atteints d’une AR progressive et d’une rétinite pigmentaire et présentant une région homozygote partagée en 6p23-p21 m’a permis d’identifier la mutation faux-sens p.Ala912Val dans le gène PEX6. L'analyse rétrospective des marqueurs du peroxysome a montré un taux d’acide phytanique sérique très modérément augmenté, alors que les fibroblastes m’ont permis de confirmer le caractère pathogène de la mutation p.Ala912Val par l'absence de marquage à la catalase, la présence de structures peroxysomales anormales et une nette augmentation des AGTLC, indiquant une perte de fonction partielle de la protéine PEX6. Par conséquent, en dépit d’une liaison génétique initiale erronée, l’entité SCAR3 est confirmée et est causée par certaines mutations du gène PEX6 (Guissart et al. Eur J Hum Genet 2016). En conclusion, la présence des mutations faux-sens hypomorphes dans ces familles et les données de la littérature démontrent le concept selon lequel de nombreuses AR sont causées par des mutations de type « perte de fonction partielle » touchant une grande variété de voies physiopathologiques, ceci en raison de l’extrême sensibilité des neurones cérébelleux, spino-cérébelleux et sensitifs profonds, à des désordres métaboliques même légers.

  • Open Access

    Improving ALS Molecular Diagnosis Through Functional Assays: Reassessment of a SOD1 Variant of Uncertain Significance

    by Léa Bedja-Iacona, Arthur Forget, Chloé Boisseau, Sylviane Marouillat, Aleksandra Chudinova, Charlotte Veyrat-Durebex, Claire Guissart, Serge Lumbroso, Cédric Raoul, Christian R. Andres, et al.

    Genetic testing in amyotrophic lateral sclerosis (ALS) often reveals variants of uncertain significance (VUS), which are frequently omitted from diagnostic reports or reported with limited clinical interpretation. To address this gap, we developed a rapid functional assessment pipeline in collaboration with FILSLAN, the French ALS care network, combining in vitro and in vivo neurogenetic assays. We illustrate this approach through the reclassification of the SOD1 p.Val120Leu variant, identified in an ALS patient, as pathogenic. Functional studies demonstrated that this variant leads to cytoplasmic aggregation, reduced neurite outgrowth, and abnormal motor behavior in zebrafish. These results support the systematic use of functional assays to clarify the pathogenicity of uncertain variants, thereby improving diagnostic accuracy, preventing misdiagnosis, and enabling timely therapeutic interventions in ALS.

  • Open Access

    A Novel De Novo Missense Mutation in KIF1A Associated with Young-Onset Upper-Limb Amyotrophic Lateral Sclerosis

    by Emilien Bernard, Florent Cluse, Adrien Bohic, Marc Hermier, Cédric Raoul, Pascal Leblanc, Claire Guissart

    We investigate the etiology of amyotrophic lateral sclerosis (ALS) in a 35-year-old woman presenting with progressive weakness in her left upper limb. Prior to sequencing, a comprehensive neurological work-up was performed, including neurological examination, electrophysiology, biomarker assessment, and brain and spinal cord MRI. Six months before evaluation, the patient experienced weakness and atrophy in her left hand, accompanied by brisk reflexes and Hoffman sign in the same arm. Electroneuromyography revealed lower motor neuron involvement in three body regions. Neurofilament light chains were elevated in her cerebrospinal fluid. Brain imaging showed asymmetrical T2 hyperintensity of the corticospinal tracts and T2 linear hypointensity of the precentral gyri. Trio genome sequencing identified a likely pathogenic de novo variant in the KIF1A gene (NM_001244008.2): c.574A>G, p.(Ile192Val). Pathogenic variants in KIF1A have been associated with a wide range of neurological manifestations called KIF1A-associated neurological diseases (KAND). This report describes a likely pathogenic de novo variant in KIF1A associated with ALS, expanding the phenotypic spectrum of KAND and our understanding of the pathophysiology of ALS.


  • Open Access

    A Novel de Novo Missense Mutation in KIF1A Associated with Young-Onset Upper-Limb Amyotrophic Lateral Sclerosis

    by Emilien Bernard, Florent Cluse, Adrien Bohic, Marc Hermier, Cédric Raoul, Pascal Leblanc, Claire Guissart

    Objectives: To investigate the etiology of amyotrophic lateral sclerosis (ALS) in an adult female patient. Methods: We conducted trio genome sequencing on a 35-year-old woman with progressive weakness in her left upper limb, as well as on her parents. Prior to sequencing, we performed a comprehensive neurological work-up on the patient, including neurological exam, electrophysiology, biomarker assessment, and brain and spinal cord MRI. Results : The propositus experienced weakness and atrophy in her left hand 6 months before the evaluation. This was associated with brisk reflexes and Hoffman sign in the same arm. Electroneuromyography revealed lower motor neuron involvement in three body regions. Neurofilament light chains were elevated in her cerebrospinal fluid. Brain imaging showed asymmetrical T2 hyperintensity of the corticospinal tracts and T2 linear hypointensity of the precentral gyri. Genome trio sequencing identified a likely pathogenic de novo variant in the propositus’s KIF1A gene (NM_001244008.2): c.574A>G, p.(Ile192Val). Discussion: Pathogenic variants in the KIF1A gene have been associated with a wide range of neurological manifestations called KIF1A-associated neurological diseases (KAND). The present report describe a likely pathogenic de novo variant in KIF1A associated with ALS, expanding the phenotypic spectrum of KAND and our understanding of the pathophysiology of ALS.

  • MostSOD1mutations are pathogenic, and their identification can lead to early access to treatment

    by Elisa De La Cruz, Florence Esselin, Anne Polge, Kévin Mouzat, Claire Guissart

    About 10% to 20% of ALS are familial (fALS), meaning that at least one other member of the family is affected by the disease. In these families, a genetic cause is identified in 48% of cases within populations of European origin.2 However, sporadic forms of ALS are also found to be undermined by genetic mutations, the most frequent being the C9ORF72 GGGGCC-repeat expansion in intron 1A, followed by mutations in superoxide dismutase type 1 (SOD1) in Caucasian populations.


  • Open Access

    Corrected speciation and gyromitrin content of false morels linked to ALS patients with mostly slow-acetylator phenotypes

    by Emmeline Lagrange, Marie-Anne Loriot, Nirmal K. Chaudhary, Pam Schultz, Alden C. Dirks, Claire Guissart, Timothy Y. James, Jean Paul Vernoux, William Camu, Ashootosh Tripathi, et al.


  • HeterozygousSPTLC1p.Leu39del is a major cause of slow-progressing juvenile ALS

    by Claire Guissart, Elisa De la Cruz, Olivier Flabeau, Aude-Marie Grapperon, Giovanni Corazza, Lucie Junilhon, Jean-Charles Delmas, Stéphanie Millecamps, Anne Polge, Maria del Mar Amador, et al.

    We performed molecular analysis of 1130 patients with ALS, with 50 of them meeting the criteria for juvenile ALS. Plasma lipid profile of patients with SPTLC1 mutation were analysed using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) and tandem mass spectrometry (MS/MS).


  • Open Access

    Discovering the ANK2‐related autism phenotype

    by Claire Guissart, Anne Polge, Nelly Durand, Ania Miret, Serge Lumbroso, Christine Francannet, Kevin Mouzat

    Interestingly, disease-causing mutations in the ANK2 gene have been identified in patients with autism since 2012, though with no full clinical description. In this Research Letter, for the first time, we describe the detailed characteristics of a patient with autism caused by a new mutation in this gene. Our report is a first step to better understanding ANK2-related autism and will contribute to facilitating its further diagnosis.


  • Open Access

    Premature termination codons in SOD1 causing Amyotrophic Lateral Sclerosis are predicted to escape the nonsense-mediated mRNA decay

    by Claire Guissart, Kevin Mouzat, Jovana Kantar, Baptiste Louveau, Paul Vilquin, Anne Polge, Cédric Raoul, Serge Lumbroso

    Amyotrophic lateral sclerosis (ALS) is the most common and severe adult-onset motoneuron disease and has currently no effective therapy. Approximately 20% of familial ALS cases are caused by dominantly-inherited mutations in the gene encoding Cu/Zn superoxide dismutase (SOD1), which represents one of the most frequent genetic cause of ALS. Despite the overwhelming majority of ALS-causing missense mutations in SOD1, a minority of premature termination codons (PTCs) have been identified. mRNA harboring PTCs are known to be rapidly degraded by nonsense-mediated mRNA decay (NMD), which limits the production of truncated proteins. The rules of NMD surveillance varying with PTC location in mRNA, we analyzed the localization of PTCs in SOD1 mRNA to evaluate whether or not those PTCs can be triggered to degradation by the NMD pathway. Our study shows that all pathogenic PTCs described in SOD1 so far can theoretically escape the NMD, resulting in the production of truncated protein. This finding supports the hypothesis that haploinsufficiency is not an underlying mechanism of SOD1 mutant-associated ALS and suggests that PTCs found in the regions that trigger NMD are not pathogenic. Such a consideration is particularly important since the availability of SOD1 antisense strategies, in view of variant treatment assignment.